Gemcitabine
AVGEMSI, GEMCITABINE
Nucleoside Metabolic Inhibitor
NADAC/unit
N/A
No Shortage
13 Manufacturers
35 ANDAs
Gemcitabine interferes with DNA synthesis to slow cancer cell or viral replication.
Active Shortages
2025-09-11 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
2025-09-11 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
2025-09-11 Discontinuation of the manufacture of the drug, Hospira, Inc., a Pfizer Company
Generic Manufacturers
ACCORD HEALTHCARE INCAVYXA HOLDINGS LLCDR REDDYS LABORATORIES LTDFRESENIUS KABI USA LLCGLAND PHARMA LTDHIKMA PHARMACEUTICALS INTERNATIONAL LTDHOSPIRA INCHOSPIRA WORLDWIDE, INCJANSSEN BIOTECH INCJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDMEITHEAL PHARMACEUTICALS INCMYLAN LABORATORIES LTDSAGENT PHARMACEUTICALS INCSHILPA MEDICARE LTDSUN PHARMACEUTICAL INDUSTRIES LTDTEYRO LABS PRIVATE LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.